Investment Banking
Oppenheimer & Co. Inc. acted as Joint Bookrunner on City Therapeutics’ $230.0MM IPO
October 21, 2026
Oppenheimer & Co. Inc. acted as Joint Bookrunner on City Therapeutics’ $230.0MM Initial Public Offering
City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, announced the closing of its upsized initial public offering of 12,777,777 shares of its common stock at a public offering price of $18.00 per share, which includes 1,666,666 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to City from the offering, including full exercise of the underwriters’ option to purchase additional shares, were approximately $230.0 million, before deducting underwriting discounts and commissions and offering expenses payable by City. All of the shares of common stock were offered by City.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Name:
Arif Sheikh
Title:Managing Director, Healthcare Life Sciences Investment Banking
Name:
Matthew Karpf
Title:Executive Director, Healthcare Life Sciences Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 9191053.1